Aurobindo Pharma, a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, has received final approval for Fosinopril Sodium and Hydrocholorothizide Tablets USP 10/12.5 mg and 20/12.5 mg from the US Food and Drug Administration (USFDA).
Fosinopril Sodium and Hydrocholorothizide Tablets USP 10/12.5 mg and 20/12.5 mg is the generic equivalent to Monopril HCT(R) Tablets 10/12.5 mg and 20/12.5 mg of Bristol Myers Squibb. Fosinopril Sodium and Hydrocholorothizide Tablets are indicated for hypertension and fall under the Cario Vascular System (CVS) theraputic segment.
The product will be launched shortly.
Aurobindo now has a total of 96 ANDA approvals (69 final approvals and 27 tentative approvals from USFDA).
